Glucocaps
Zein nanoparticles for glycemic control (sugar absortion)
The Nutrition Research Center and the biotechnology company NUCAPS are launching a nutritional intervention study in people with high blood sugar levels, known as prediabetes.
A high level of glucose poses very serious health risks, in addition to causing symptoms such as fatigue, nausea and vomiting, shortness of breath or stomach pain, it can damage the blood vessels that carry blood to vital organs, which increases the risk of heart disease, strokes, kidney diseases, vision problems and neurological problems.
On the other hand, an uncontrolled level of sugar can develop type 2 diabetes that requires pharmacological treatment mainly with insulin injections and affects both quality of life and longevity.
To date there is no effective treatment, and the only tools we have are: regular physical activity and strict diet control to avoid overweight to try to control glucose levels.
The product that will be tested for 15 weeks, with 60 volunteers, is a vegetable protein from corn, a nutritional supplement of natural origin usually used in food, which will be taken orally in capsules. It is an effective treatment without side effects to prevent and combat metabolic diseases, such as diabetes and obesity, and we hope to safely increase both life expectancy and quality of it.
- Title: GLUCOCAPS, zein nanoparticles for glycemic control (sugar absortion)
- Identification Number: 0011-1365-2021-000107
- Implementation period: November 2021-November 2023
- Partners:NUCAPS NANOTECHNOLOGY S.L. and UNIVERSIDAD DE NAVARRA
This project has been approved and financed by the Government of Navarre in the Strategic R&D projects 2019-2021 call and it is co-financed (50%) by the FEDER funds through the Programa Operativo 2014-2020 de Navarra.
This enterprise has received a 50% co-financed grant by the European Regional Development Fund through the Programa Operativo FEDER 2014-2020 de Navarra.
